Newsroom

Sorted by: Latest

-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules, today announced its $130 million Series B financing round co-led by Oak HC/FT and General Catalyst. This round of financing values the company at $1.3 billion. The news comes on the heels of Chai’s most recent announcement1, where the company showed their latest models can now design molecules with important “developability” properties and tackle “hard-to-d...
-

Trinseo Announces Receipt of Notice of Non-Compliance With NYSE Continued Listing Requirements

WAYNE, Pa.--(BUSINESS WIRE)--Trinseo™ PLC (NYSE: TSE), a specialty material solutions provider (“Trinseo” or the “Company”), today announced that on December 12, 2025, the Company received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) informing the Company that it is not currently in compliance with Section 802.01B of the NYSE Listed Company Manual (the “minimum market capitalization standard”) because its 30 trade-day average market capitalization was less than the NYSE...
-

NUBURU Secures $25 Million Financing, Advancing Integrated Defense & Security Platform

CENTENNIAL, Colo.--(BUSINESS WIRE)--NUBURU, Inc. (NYSE American: BURU), a global pioneer in high-performance blue laser technology, today announced that it has entered into a Securities Purchase Agreement with YA II PN, Ltd. pursuant to which it will receive a gross cash infusion of $23.25 million in exchange for the issuance of a $25.0 million unsecured debenture and related warrant packages. The financing will significantly strengthen NUBURU’s capital position and enable the Company to accele...
-

Madison River Capital Appoints Bob Barthelmes as Operating Advisor and Board Member of JDC Power Systems

NEW YORK--(BUSINESS WIRE)--Madison River Capital (“MRC”), a lower middle market private equity firm, today announced the appointment of senior technology executive Robert (“Bob”) Barthelmes as an Operating Advisor. Barthelmes has also been appointed as a member of the Board of Directors of MRC portfolio company JDC Power Systems, a leading electrical systems integrator exclusively serving the data center market. Barthelmes brings more than 30 years of experience across enterprise technology, di...
-

Accord Announces Banking Facility Update and Proposed Debenture Amendments

TORONTO--(BUSINESS WIRE)--Accord Announces Banking Facility Update and Proposed Debenture Amendments...
-

ICE Launches TTF Daily Options and Announces Record Trading Across TTF and JKM Natural Gas

AMSTERDAM & LONDON--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE:ICE), a leading global provider of technology and data and home to the largest markets in the world to trade energy derivatives, today announced the launch of TTF Daily Options, as well as record trading through 2025 across ICE’s TTF futures and options markets, including TTF 1st Line Financial futures, as well as JKM LNG (Platts) natural gas futures. TTF Daily Options, which launched for trading on December 8, 2025, are...
-

Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to-Moderate Acute Pain

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the company has received support from the U.S. Food and Drug Administration (FDA) to advance AlgiaPak® toward a Phase 2 clinical trial upon completion of Investigational New Drug (IND)-enabling studies. AlgiaPak is the company’s streamlined, multimodal pain formulation designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. The company ha...
-

Farmland Partners Declares $0.20 per Share Special Dividend

DENVER--(BUSINESS WIRE)--Farmland Partners Inc. (NYSE: FPI) (the “Company” or “FPI”) today announced that its Board of Directors has declared a one-time dividend of $0.20 per share of common stock and Class A Common OP Unit, payable in cash on January 7, 2026 to shareholders of record on December 23, 2025. The special dividend is in addition to the quarterly dividend of $0.06 per share of common stock and Class A Common OP Unit that FPI declared on October 28, 2025. For more details on the quar...
-

Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). Zoetis also intends to grant the initial purchasers of the Notes an op...